EXEL Exelixis Inc
Company Analysis
Latest News
BlackRock buys $1.58 billion Exelixis stake, following recent stock volatility
BlackRock Inc. disclosed a substantial new stake in Exelixis on August 21, 2026. The asset management firm purchased 29.1 million shares. This acquisition is...
AQR Capital Management Takes 4.39% Exelixis Stake, Amid Valuation Disconnect
AQR Capital Management disclosed a 4.39% stake in Exelixis, Inc. The investment firm now holds 11,023,943 shares. A Schedule 13G/A filing on August 12, 2026,...
🔴 Exelixis is trading 5.8% down today after a 2026 revenue guidance cut
Exelixis is trading 5.8% down now at $53.41 after management lowered full-year 2026 total-revenue guidance. - August 5 earnings showed second-quarter revenue...
🔴 Exelixis is trading 5.4% down today after guidance cut and soft Q2 revenue
Exelixis is trading at $53.64 (down 5.4%) after its Q2 earnings report showed weaker-than-expected revenue and a significant cut to full-year 2026 guidance. •...
🔴 Exelixis is trading 4.76% down today after Q2 revenue miss and full-year guidance cut
Exelixis is trading at $54.00 (4.76% down) after its August 5, 2026 earnings update missed revenue estimates and prompted a cut to full-year guidance. The...
Exelixis misses second quarter revenue expectations and lowers its full-year 2026 guidance.
Exelixis reported second quarter total revenues of $628.7 million, missing consensus estimates of $636.4 million, while non-GAAP diluted EPS of $0.91 surpassed...
Exelixis Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect Exelixis to report consensus revenue of $636.40 million and non-GAAP EPS of $0.85, with the stock currently...
🔴 Exelixis is trading 4.1% down today amid broader biotech weakness
Exelixis is trading 4.06% down at $53.70 as the broader biotech sector faces selling pressure. • The move appears to track the SPDR S&P Biotech ETF (XBI),...
Exelixis Hits 52-Week High, Fueled by Oncology Pipeline Optimism
Exelixis Inc. (EXEL) reached a new 52-week high on July 8, 2026. This milestone signals strong upward momentum for the biotechnology firm. Positive analyst...
Exelixis Confronts Mixed Zanzalintinib Data, Following Russell Index Removal
Exelixis faces heightened investor scrutiny following mixed subgroup data from its STELLAR-303 trial for zanzalintinib. This trial targeted metastatic...
🟢 EXEL is trading 5.2% up in pre-market with no clear catalyst yet
EXEL is trading at 5.2% up now at $56.78 in pre-market, a strong move versus its recent tight trading range. So far, there are no fresh earnings, FDA, M&A, or...
Exelixis Shares Fall, as Key Cancer Trial Misses Statistical Significance
Exelixis reported mixed results from its Phase 3 STELLAR-303 trial for the cancer drug zanzalintinib. The trial evaluated the drug in combination with...
🟢 Exelixis Inc is trading 4.9% up today amid positive risk sentiment and broader market strength
Exelixis Inc is trading at $55.00 (4.9% up) in pre-market, extending its recent upward drift after closing at $52.44 on June 17, 2026. • Broader U.S. equity...